Agree, Dr Priscilla Brastianos has always championed Paxalisib (GDC-0084) for her preference in the PI3K arm of the ALLIANCE trial.
It is a closed shop as for any trial information leaking out of her Lab.
IMO the analysts have not valued the progress of this study, Huge potential for a Kazia share re-rating on the release of positive news.
Regards.
- Forums
- ASX - By Stock
- KZA
- Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted Therapeutics
Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted Therapeutics, page-3
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online